



CMTRA

The Cancer Molecular Therapeutics
Research Association

Cancer Molecular Therapeutics Research Association 2026 Annual Meeting Snowbird Resort | July 12-16, 2026 Program and Schedule

Sunday, July 12

Day 1

4:00-6:00 pm **Registration & Check-In**
Main Lobby

6:00-7:00 pm **Dinner**
Wasatch Room

7:30-7:45 pm **Welcome and Introduction**
*Dr. Martin McMahon, PhD; CMTRA Board President
Professor of Dermatology and Senior Director, Preclinical Translation
University of Utah and Huntsman Cancer Institute
Superior Room*

7:45-8:45 pm **Keynote Speaker: "Predictive Oncology: Decoding Genomic, Host, and Immune Determinants of Cancer Progression."**
*Christina Curtis, PhD, MSc
RZ Cao Professor and Professor of Genetics
Stanford University*

9:00-10:30 pm **Welcome Reception**
Wasatch Room

Monday, July 13

Day 2

7:30-8:15 am **Breakfast**
Wasatch Room

8:30 am-
12:00 pm **Morning Session: Novel Approaches to Targeting Cancer Vulnerabilities**
*Discussion Leader: Bob Abraham, PhD; CMTRA Board Member
CSO, Engine Biosciences
Superior Room*

8:30-8:45 am **Session Introduction**
Bob Abraham, PhD

8:45-9:15 am **"Activation Lethality: A New Approach to Targeted Therapy"**
*Matt Niederst, PhD
VP, Head of Biology
Halda Therapeutics*

Monday, July 13 continued

Day 2

9:45-10:15 am **Open Discussion**

9:45-10:00 am **Coffee Break**

Superior Lobby

10:00-10:30
am

“RIPTACs: A Novel, Powerful Modality to Treat Patients with Prostate Cancer and Other Diseases”

*Edmond Chipumuro, PhD
Director, Target Biology
Halda Therapeutics*

10:30-11:00
am **Open Discussion**

11:00-11:30
am **“Targeting the Inverted Proteome”**

*Corleone Delaveris, PhD
Co-founder
Inversion Therapeutics*

11:30 am-
12:00 pm

Open Discussion

12:00-1:00 pm **Lunch**

Superior Lobby

1:00-5:00 pm **Open afternoon for networking**

Activities at Snowbird: swimming, tram rides, mountain biking, hiking, spa, etc. See hotel for more info.

5:00-6:30 pm **Poster Session and Social**

Superior Lobby

6:30-7:30 pm

Dinner

Superior Lobby

7:30-9:45 pm **Evening Session: Lineage Plasticity in Cancer**

*Discussion Leader: Aria Vaishnavi, PhD; CMTRA Board Member
Assistant Professor, Cancer Biology
MD Anderson
Superior Room*

7:30-7:45 pm **Session Introduction**

Aria Vaishnavi, PhD

7:45-8:15 pm **“Modeling Lineage Plasticity and Metastasis in Prostate Cancer”**

*Cory Abate-Shen, PhD
Professor of Urological Oncology
Columbia University*

8:15-8:45 pm **Open Discussion**

8:45-9:15 pm **“Non-canonical PI3K-gamma signaling is a lineage-specific vulnerability of tuft-like cancer”**

*Trudy Oliver, PhD
Professor of Pharmacology and Cancer Biology
Duke University*

9:15-9:45 pm **Open Discussion**

Monday, cont'd | Tuesday, July 14

Day 3

10:00 pm	Social <i>Hospitality Suite- Mt. Superior Room</i>
7:30-8:15 am	Breakfast <i>Superior Lobby</i>
8:30 am- 12:00 pm	Morning Session: PDAC <i>Discussion Leader: Martin McMahon, PhD; CMTRA Board President Huntsman Cancer Institute Superior Room</i>
8:30-8:45 am	Introduction <i>Martin McMahon, PhD</i>
8:45-9:15 am	“Evolution of the pancreatic cancer microenvironment” <i>Marina Pasca di Magliano, PhD Professor of Surgery, Surgical Immunology & Cell and Developmental Biology University of Michigan</i>
9:15-9:45 am	Open Discussion
9:45-10:00 am	Group Photograph and Coffee Break <i>Superior Lobby</i>
10:00-10:30 am	“Organelle based adaptive mechanisms during pancreatic cancer metastasis” <i>Rushika Perera, PhD Professor, Department of Anatomy, School of Medicine UCSF</i>
10:30-11:00 am	Open Discussion
11:00-11:30 am	“Clonal Heterogeneity in Human Pancreatic Cancer: Impact on Tumor Progression” <i>Diane Simeone, MD Professor of Surgery UCSD</i>
11:30 am- 12:00 pm	Open Discussion
12:00-1:00 pm	Lunch <i>Superior Lobby</i>
1:00-5:00 pm	Open afternoon for networking- World Cup Semifinals in Hospitality Suite <i>Activities at Snowbird: swimming, tram rides, mountain biking, hiking, spa, etc. See hotel for more info.</i>
5:00-6:30 pm	Panel Discussion: AI/ML <i>Discussion Leader: Hans Bitter/Emma Lees Panelists: Surge Biswas- Nabla Bio Elliot Hershberg- Amplify Ian Quigley- Leash Bio</i>
6:30-7:30 pm	Dinner <i>Superior Lobby</i>

Tuesday, July 14, continued

Day 3

- 7:30-9:45 pm** **Evening Session: Hormone-Dependent Cancers**
 Discussion Leader: Melissa Junttila, PhD
 Vice President, Head of Biology
 Oric Pharmaceuticals
 Superior Room
-
- 7:30-7:45 pm** **Introduction**
 Discussion Leader: Melissa Junttila, PhD
-
- 7:45-8:15 pm** **“Modeling Breast Cancer to Advance Therapeutic Strategies”**
 Alana Welm, PhD
 Chair and Professor, Department of Oncological Sciences
 University of Utah and Huntsman Cancer Institute
-
- 8:15-8:45 pm** **Open Discussion**
-
- 8:45-9:15 pm** **“Understanding the mechanisms by which cells recognize and respond to different levels of androgens has informed new therapeutic approaches for prostate cancer”**
 Donald McDonnell, PhD
 Glaxo-Wellcome Distinguished Professor of Molecular Cancer Biology, Professor of Pharmacology and Cancer Biology, Professor in Medicine, Professor of Cell Biology
 Duke University
-
- 9:15-9:45 pm** **Open Discussion**
-
- 9:45 pm** **Social**
 Hospitality Suite- Mt. Superior Room

Wednesday, July 15

Day 4

- 7:30-8:15 am** **Breakfast**
 Superior Lobby
-
- 8:30 am-12:00 pm** **Morning Session: Stress and Resistance**
 Discussion Leader: Ralph De Berardinis, MD, PhD; CMTRA Board Member
 Director of the Eugene McDermott Center for Human Growth and Development;
 Director, Genetic and Metabolic Disease Program
 UT Southwestern
 Superior Room
-
- 8:30-8:45 am** **Introduction**
 Ralph De Berardinis, PhD
-
- 8:45-9:15 am** **“Ferroptosis and the metastatic microenvironment”**
 Jessalyn Ubellacker, MD, PhD
 Assistant Professor, Department of Molecular Metabolism
 Harvard T.H. Chan School of Public Health
-
- 9:15-9:45 am** **Open Discussion**
-
- 9:45-10:00 am** **Coffee Break**
 Superior Lobby

Wednesday, July 15, continued

Day 4

10:00-10:30 am	<p>"Molecular Glues in endogenous signaling and cancer therapy."</p> <p><i>Micha Rapé, PhD</i> Professor, Division of Molecular Therapeutics UC Berkeley</p>
10:30-11:00 am	<p>Open Discussion</p>
11:00-11:30 am	<p>"Exploiting Genomic and Lineage-State Vulnerabilities in Small Cell Lung Cancer"</p> <p><i>Matt Oser, MD, PhD</i> Associate Professor of Medicine Dana Farber Cancer Institute</p>
11:30 am-12:00 pm	<p>Open Discussion</p>
12:00-1:00 pm	<p>Lunch</p> <p><i>Superior Lobby</i></p>
1:00-2:00 pm	<p>Break- World Cup Semifinals Broadcast in Hospitality Suite</p>
2:00-5:00 pm	<p>Afternoon Session: Chemical Biology</p> <p><i>Discussion Leader: Mat Patricelli, PhD; CMTRA Board Member</i> Chief Scientific Officer Vividion Therapeutics Superior Room</p>
2:00-2:15 pm	<p>Introduction</p> <p><i>Matt Patricelli, PhD</i></p>
2:15-2:45 pm	<p>"Expanding the Chemical Tractability of the Human Proteome"</p> <p><i>Chris Parker, PhD</i> Professor, Department of Chemistry Scripps Research</p>
2:45-3:10 pm	<p>Open Discussion</p>
3:10-3:40 pm	<p>"Chemical and genetic glues of the E3 ligase oncogene KBTBD4"</p> <p><i>Brian Liao, PhD</i> Associate Professor, Department of Chemistry and Chemical Biology Harvard University</p>
3:40-4:05 pm	<p>Open Discussion</p>
4:05-4:35 pm	<p>"Interrogating the Druggable Proteome with Proximity Pharmacology"</p> <p><i>Fleur Ferguson, PhD</i> Assistant Professor of Chemistry and Biochemistry UCSD</p>
4:35-5:00 pm	<p>Open Discussion</p>
5:00-6:00 pm	<p>Break</p>

Wednesday, July 15, continued

Day 4

6:00-7:00 pm **Dinner**
Superior Lobby

7:15-8:15 pm **Closing Keynote: “How cancer cells escape targeted therapy by changing identity”**
*Charles Sawyers, PhD
HHMI Investigator, Chair of Human Oncology and Pathogenesis Program
Memorial Sloan Kettering Cancer Center
Superior Room*

8:30-10:00 pm **Closing Reception**
Superior Lobby

Thursday, July 16

Day 5

Onsite breakfast options:

*The Atrium- Cliff lodge
Seventy One- Cliff Lodge
Creekside Cafe + Grill- Snowbird Center
General Gritts Bodega- Snowbird Center
Sidecar Coffee- Snowbird Center
Baked and Brewed Coffee- Snowbird Center*

11:00 am **Departure & Checkout**
Check out time: 11:00 am

IMPORTANT NOTICE: By attending this conference, you agree to respect the confidentiality of the proceedings. Specifically, photographing or recording of sessions, posters or discussions is not permitted. Reference to material presented or discussed may not be included in any publication. Permission to cite information may subsequently be obtained directly from the presenter and is beyond the control of the meeting organizers.

THIS MEETING WOULD NOT BE POSSIBLE WITHOUT THE GENEROUS CONTRIBUTIONS FROM OUR MANY FRIENDS AND COLLEAGUES

**CANCER MOLECULAR THERAPEUTICS RESEARCH ASSOCIATION
ANNUAL CONFERENCE 2026**



CMTRA

The Cancer Molecular Therapeutics
Research Association

Thanks to our 2026 sponsors:



ATAVISTIK



BridgeBio Oncology Therapeutics



Bristol Myers Squibb®

Genentech

The original biotech company



GILEAD



NOVARTIS

Lilly



Revolution
Medicines

SUTRO 
BIOPHARMA

vividion TM
THERAPEUTICS

CMTRA 2026 Poster Session | Monday, July 13 5:00 pm | Superior Lobby

1	Kayla Nutsch, PhD	kayla.nutsch@bbotx.com	BBOT	BBO-11818: an orally bioavailable, highly potent and selective non-covalent pan-KRAS(ON) and (OFF) inhibitor with robust anti-tumor activity in KRAS-mutant preclinical models
2	Reilly Falter	reilly.falter@hci.uta.h.edu	HCI	SOX2 is a master regulator of classical squamous cell carcinoma
3	Karsten Eastman	karsten@setheratx.com	Sethera	High-Throughput Discovery of Polymacrocyclic Peptides for Targeting Oncologic Drivers
4	Kate Warde	kate.warde@hci.uta.h.edu	HCI	“Androgens promote anti-tumor immunity in adrenal cancer”
5	Sanjana Srinivas Boggaram	sanjana.boggaram@hci.utah.edu	HCI	Investigating the role of AKT protein kinases in lung cancer.
6	Hannah Neuendorf	hannah.neuendorf@hci.utah.edu	HCI	‘Investigating the role of the NRAS ó PI3’Kα signaling axis in NRAS-driven melanoma’.
7	Maha Moussa	"maha.moussa@usu.edu	USU	Leakage-Controlled Deep Learning for Prostate Cancer Histopathology: A Case-Aware Comparison of Majority-Vote and Soft-Label Supervision
8	Said Elshafae	u6053028@umail.utah.edu	HCI	CD79b SynNotch-Gated CD19 BBζ CAR-T Cells Sustain Anti-Leukemia Activity and Preserve T-Cell Fitness in B-ALL
9	Yi Qiao	yi.qiao@utah.edu	HCI	A generalizable software framework for ultra-rapid sequence analysis and its application in enabling 1 day deep multi-omic data analysis turnaround for brain cancer precision oncology
10	Henry Arnold	henry.arnold@hci.utah.edu	HCI	Investigating the impact of oncogenic signaling on pulmonary and gastrointestinal identity programs in lung adenocarcinoma
11	Melissa Junttila	melissa.junttila@oricpharma.com	Oric Pharma	
12	Headtlove Essel Dadzie	Headtlove.esseldadzie@hci.utah.edu	HCI	HNF4α controls lineage identity and therapeutic response in Invasive Mucinous Adenocarcinoma of the lung.
13	Bill Schary	bill@7hillspharma.com	7 Hills Pharma	A phase 1b dose-escalation study of the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of alintegimod (ALIN) + ipilimumab (Ipi) followed by nivolumab (Nivo) in advanced solid tumor patients
14	Brandon Murphy	brandon.murphy@hci.utah.edu	HCI	Delineating the mechanisms enabling lung adenocarcinomas to overcome dependence on WNT/β-catenin signaling
15	Beatrice Knudsen	beatrice.knudsen@path.utah.edu	HCI	FoxA2 and ONECUT2 mIF Phenotypes in Prostate Cancer
16				